Teva Pharmaceutical Industries (NYSE:TEVA) was downgraded by JPMorgan Chase & Co. from a “neutral” rating to an “underweight” rating in a research note issued to investors on Monday, November 13th, Marketbeat reports. They currently have a $11.00 target price on the stock, down from their prior target price of $11.48. JPMorgan Chase & Co.’s price target would indicate a potential downside of 41.95% from the stock’s previous close.
Other equities research analysts have also issued reports about the stock. BidaskClub lowered shares of Teva Pharmaceutical Industries from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 16th. Citigroup lowered shares of Teva Pharmaceutical Industries from a “buy” rating to a “neutral” rating and cut their price objective for the company from $32.00 to $19.00 in a report on Wednesday, August 16th. Credit Suisse Group reaffirmed an “outperform” rating and set a $39.00 price objective on shares of Teva Pharmaceutical Industries in a report on Wednesday, August 9th. Cantor Fitzgerald set a $17.00 price objective on shares of Teva Pharmaceutical Industries and gave the company a “hold” rating in a report on Monday, September 11th. Finally, Zacks Investment Research raised shares of Teva Pharmaceutical Industries from a “sell” rating to a “hold” rating in a report on Monday, July 17th. Five investment analysts have rated the stock with a sell rating, nineteen have assigned a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $20.99.
Teva Pharmaceutical Industries (NYSE:TEVA) traded down $0.05 during trading on Monday, reaching $18.95. 10,559,214 shares of the company traded hands, compared to its average volume of 27,233,690. The stock has a market cap of $19,253.20, a price-to-earnings ratio of -3.18 and a beta of 0.55. Teva Pharmaceutical Industries has a one year low of $10.85 and a one year high of $38.31. The company has a quick ratio of 0.66, a current ratio of 0.96 and a debt-to-equity ratio of 1.20.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
